<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549886</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-MGD-11-201</org_study_id>
    <nct_id>NCT01549886</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy and safety of the Zevalin regimen&#xD;
      compared to Zevalin and motexafin gadolinium in patients with rituximab-refractory, low-grade&#xD;
      or follicular Non-Hodgkin's Lymphoma (NHL).&#xD;
&#xD;
      Effectiveness of the experimental regimen assessed by complete response rate within 6 months&#xD;
      of study entry (primary endpoint), complete response rate within 3 months of study entry, and&#xD;
      overall response rate within 6 month of study entry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, randomized, open-label study is designed to compare the safety and&#xD;
      efficacy of therapy with Zevalin regimen versus Zevalin and motexafin gadolinium in patients&#xD;
      with rituximab-refractory, low-grade or follicular NHL. Approximately 100 adult patients&#xD;
      enrolled in the study (approximately 50 in each group at 15 clinical sites in North America).&#xD;
&#xD;
      Patients screened for eligibility within the 14 days prior to Day 1 of the study. Once&#xD;
      written informed consent has been obtained and patient eligibility has been established, the&#xD;
      patient randomized 1:1 to receive either Zevalin or Zevalin and motexafin gadolinium.&#xD;
&#xD;
      Patients assessed for safety at each visit to the study center and for disease response at&#xD;
      Months 3, 6 and 12. An end-of-study-visit performed at Month 12.&#xD;
&#xD;
      Disease status assessed using positron emission tomography (PET) or PET/computerized&#xD;
      tomography (CT), and/or flow cytometry. Disease response will be evaluated in accordance with&#xD;
      the standardized definitions and criteria of the International Working Group Revised Response&#xD;
      Criteria for Malignant Lymphoma. The efficacy endpoints that assessed are complete response&#xD;
      rate and overall response rate.&#xD;
&#xD;
      Safety was assessed by adverse events, physical examinations, vital signs, and clinical&#xD;
      laboratory assessments. Serious adverse events (SAEs) and treatment-emergent adverse events&#xD;
      (TEAEs) was collected for all patients beginning on Day 1 and continuing through the end-of&#xD;
      study-visit to be performed at Month 12 or withdrawal from study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to business reasons.&#xD;
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate (CR)</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>3 Months and 6 Months</time_frame>
    <description>Complete response rate within 3 months, overall response rate within 6 months and progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events and Non-Serious Adverse Events</measure>
    <time_frame>From time of dosing until 2 years</time_frame>
    <description>An Adverse Events (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Non-SAEs was an AE events that are not Serious Adverse Events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>MGD + Rituximab + Y-90-Zevalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab + Y-90-Zevalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Y-90-Zevalin</intervention_name>
    <description>Day 8 - Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push</description>
    <arm_group_label>MGD + Rituximab + Y-90-Zevalin</arm_group_label>
    <arm_group_label>Rituximab + Y-90-Zevalin</arm_group_label>
    <other_name>[90Y]- ibritumomab tiuxetan (Zevalin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxtezafin Gadolinium</intervention_name>
    <description>Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily</description>
    <arm_group_label>MGD + Rituximab + Y-90-Zevalin</arm_group_label>
    <other_name>MGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Day 1 and Day 8: Rituximab 250 mg/m^2 intravenous infusion</description>
    <arm_group_label>MGD + Rituximab + Y-90-Zevalin</arm_group_label>
    <arm_group_label>Rituximab + Y-90-Zevalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women, at least 18 years of age&#xD;
&#xD;
          2. Histologically-confirmed follicular or indolent, marginal zone and small lymphocytic B&#xD;
             cell non-Hodgkin's lymphoma&#xD;
&#xD;
          3. Progressive disease within 6 months of the end of a rituximab-containing regimen; or&#xD;
             progressive disease at any time following 2 or more prior rituximab-containing&#xD;
             regimens; or progressive disease while on rituximab-containing regimen.&#xD;
&#xD;
          4. At least 1 measurable tumor (&gt; 1.5 cm in the long axis and &gt; 1.0 cm in the short axis)&#xD;
             that has not been irradiated previously or that has increased in size since previous&#xD;
             irradiation&#xD;
&#xD;
          5. A life expectancy of at least 3 months&#xD;
&#xD;
          6. A World Health Organization/Eastern Cooperative Oncology Group (WHO/ECOG) performance&#xD;
             status of 0 or 1&#xD;
&#xD;
          7. Adequate hematopoietic function: absolute neutrophil count (ANC) ≥ 1,500 cells/μL,&#xD;
             absolute lymphocyte count (ALC) ≤ 5,000 cells/μL, platelet count ≥ 100,000&#xD;
             cells/μL,hemoglobin ≥ 9 g/dL (may be transfused to maintain this concentration).&#xD;
             Patients who have received pre-phase therapy for purposes of improving performance&#xD;
             status prior to initiating Zevalin are eligible.&#xD;
&#xD;
          8. Adequate liver function: total bilirubin ≤ 2 × upper limit of normal (ULN), Aspartate&#xD;
             aminotransferase (AST) (Serum glutamic oxaloacetic transaminase [SGOT]) and Alanine&#xD;
             transaminase (ALT) (Serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × upper limits&#xD;
             of normal (ULN)&#xD;
&#xD;
          9. Creatinine clearance ≥ 60 mL/min/1.73 m^2&#xD;
&#xD;
         10. Bone marrow involvement &lt; 25%&#xD;
&#xD;
         11. If men or women of reproductive potential, agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control) prior to study entry and for at least 1&#xD;
             year following treatment with Zevalin&#xD;
&#xD;
         12. Willing and able to provide written Informed Consent and to comply with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received antineoplastic, experimental, and/or radiation therapy within the 3 weeks&#xD;
             prior to Study Day 1&#xD;
&#xD;
          2. Has not recovered to ≤ Grade 1 from all toxicities related to prior treatments&#xD;
&#xD;
          3. Prior radioimmunotherapy for NHL&#xD;
&#xD;
          4. Autologous stem cell transplant within the 3 months prior to Study Day 1, and/or any&#xD;
             history of allogeneic stem cell transplant with continued allogeneic hematopoiesis&#xD;
&#xD;
          5. Platelet transfusion within the 7 days prior to Study Day 1&#xD;
&#xD;
          6. History of porphyria&#xD;
&#xD;
          7. Grade 2 or higher peripheral neuropathy within the 14 days prior to Study Day 1&#xD;
&#xD;
          8. History of or active central nervous system disease (e.g., primary brain tumor,&#xD;
             seizures not controlled with standard medical therapy, brain metastases)&#xD;
&#xD;
          9. Ongoing, active infection that requires anti infective therapy&#xD;
&#xD;
         10. Clinically significant cardiovascular disease (e.g., unstable angina pectoris, serious&#xD;
             cardiac arrhythmia requiring medication, uncontrolled hypertension, myocardial&#xD;
             infarction, New York Heart Association [NYHA] Class 2 or higher congestive heart&#xD;
             failure, Grade 2 or higher peripheral vascular disease) within the 12 months prior to&#xD;
             Study Day 1&#xD;
&#xD;
         11. History of another clinically significant medical condition, metabolic dysfunction,&#xD;
             physical examination finding, and/or clinical laboratory finding giving reasonable&#xD;
             suspicion of a disease or condition that contraindicates use of an investigational&#xD;
             drug or that might affect interpretation of the results of the study or place the&#xD;
             patient at high risk of treatment complications and/or of noncompliance with the study&#xD;
             procedures&#xD;
&#xD;
         12. Major surgical procedure and/or significant traumatic injury (that which could&#xD;
             interfere with the patient's ability to receive protocol therapy as determined by the&#xD;
             principal investigator) within the 28 days prior to Study Day 1, and/or patient is&#xD;
             anticipated to require a major surgical procedure during the study period&#xD;
&#xD;
         13. Diagnosed with and/or treated for a malignancy other than NHL within the 2 years prior&#xD;
             to Study Day 1, with the exception of complete resection of basal cell carcinoma or&#xD;
             squamous cell carcinoma of the skin, an in situ malignancy, and/or low-risk prostate&#xD;
             cancer after curative therapy from which the patient has been disease-free for at&#xD;
             least 1 year&#xD;
&#xD;
         14. Evidence of a bleeding diathesis and/or a coagulopathy&#xD;
&#xD;
         15. Known HIV infection&#xD;
&#xD;
         16. Known hypersensitivity to drugs with porfyrin-like structures, like Visudyne™.&#xD;
&#xD;
         17. Positive Hepatitis B or C infection: Patient must be tested for hepatitis B surface&#xD;
             antigen.&#xD;
&#xD;
         18. Pregnant or lactating woman&#xD;
&#xD;
         19. Full dose oral or parenteral anticoagulants within the 10 days prior to Study Day 1,&#xD;
             and/or anticipated full dose oral or parenteral anticoagulant therapy during the study&#xD;
             period(except as required to maintain patency of pre-existing, permanent, indwelling&#xD;
             intravenous catheters) or thrombolytic agents&#xD;
&#xD;
         20. Participated in another clinical study within the 4 weeks prior to Study Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew M Evens, DO, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center-Herrick</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halifax Health- Center for Oncology</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts - Worcester</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University, WVU Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <results_first_submitted>October 16, 2015</results_first_submitted>
  <results_first_submitted_qc>September 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2021</results_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Zevalin</keyword>
  <keyword>Motexafin Gadolinium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MGD+Rituximab+Y-90-Zevalin</title>
          <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
        </group>
        <group group_id="P2">
          <title>Rituximab+Y-90-Zevalin</title>
          <description>Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Sponsor's decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MGD+Rituximab+Zevalin</title>
          <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
        </group>
        <group group_id="B2">
          <title>Rituximab+Zevalin</title>
          <description>Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="2.5"/>
                    <measurement group_id="B2" value="57" spread="6.24"/>
                    <measurement group_id="B3" value="54" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response Rate (CR)</title>
        <time_frame>6 Months</time_frame>
        <population>Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>MGD+Rituximab+Y-90-Zevalin</title>
            <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab+Y-90-Zevalin</title>
            <description>Day 1 Rituximab 250 mg/m2 intravenous infusion. Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)&#xD;
Zevalin Regimen: Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate (CR)</title>
          <population>Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Complete response rate within 3 months, overall response rate within 6 months and progression-free survival.</description>
        <time_frame>3 Months and 6 Months</time_frame>
        <population>Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>MGD+Rituximab+Zevalin</title>
            <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab+Zevalin</title>
            <description>Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Complete response rate within 3 months, overall response rate within 6 months and progression-free survival.</description>
          <population>Data for this outcome measure was not collected and analysed as no participants available for analysis and study was discontinued prematurely due to business reasons.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events and Non-Serious Adverse Events</title>
        <description>An Adverse Events (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Non-SAEs was an AE events that are not Serious Adverse Events.</description>
        <time_frame>From time of dosing until 2 years</time_frame>
        <population>Safety analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>MGD+Rituximab+Y-90-Zevalin</title>
            <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
          </group>
          <group group_id="O2">
            <title>Rituximab+Y-90-Zevalin</title>
            <description>Day 1 Rituximab 250 mg/m2 intravenous infusion. Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)&#xD;
Zevalin Regimen: Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events and Non-Serious Adverse Events</title>
          <description>An Adverse Events (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Non-SAEs was an AE events that are not Serious Adverse Events.</description>
          <population>Safety analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from time of dosing until 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MGD+Rituximab+Y-90-Zevalin</title>
          <description>Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.&#xD;
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.</description>
        </group>
        <group group_id="E2">
          <title>Rituximab+Y-90-Zevalin</title>
          <description>Day 1 Rituximab 250 mg/m2 intravenous infusion. Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL.)&#xD;
Zevalin Regimen: Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophils count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gajanan Bhat, PhD</name_or_title>
      <organization>Spectrum Pharmaceuticals</organization>
      <phone>949-743-9219</phone>
      <email>Gajanan.Bhat@sppirx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

